Cargando…
Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma
Most patients with hepatocellular carcinoma (HCC) are diagnosed when the disease is already at an advanced stage, so they are not eligible for resection and their prognosis is poor. The combination of transarterial chemoembolization (TACE) with immune checkpoint inhibitors or tyrosine kinase inhibit...
Autores principales: | Chen, Kang, Luo, Cheng-Piao, Ge, De-Xiang, Wang, Ke-Lin, Luo, Qin, Li, Yan-Zhi, You, Xue-Mei, Xiang, Bang-De, Li, Le-Qun, Ma, Liang, Zhong, Jian-Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583878/ https://www.ncbi.nlm.nih.gov/pubmed/36276151 http://dx.doi.org/10.3389/fonc.2022.946693 |
Ejemplares similares
-
Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview
por: Sun, Hui-Chuan, et al.
Publicado: (2021) -
Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study
por: Yi, Yong, et al.
Publicado: (2022) -
Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors
por: Li, Xingzhi, et al.
Publicado: (2023) -
Successful conversion therapy for unresectable hepatocellular carcinoma is getting closer: A systematic review and meta-analysis
por: Pei, Yinxuan, et al.
Publicado: (2022) -
Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma
por: Li, Binkui, et al.
Publicado: (2021)